Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Proton-linked monocarboxylate transporter. Additionally we are shipping SLC16A4 Proteins (4) and many more products for this protein.
Showing 10 out of 17 products:
This study showed that mouse MCT1 (show MCTS1 Antibodies), MCT2 (show SLC16A7 Antibodies), and MCT4 (show SLC16A3 Antibodies) are expressed in the PNS. While DRG neurons express MCT1 (show MCTS1 Antibodies), myelinating Schwann cells.
Expression of cerebral MCT (show MCAT Antibodies) isoforms can be modulated by alterations of peripheral metabolism, suggesting that the adult brain is sensitive and adapts to new metabolic states.
The reversible H(+)/lactate(-) symporter MCT4 cotransports lactate and proton, leading to the net extrusion of lactic acid in glycolytic tumors. A model of its role in pH control in tumor cells is described. Review.
Increased miR (show MLXIP Antibodies)-210 and concomitant decreased ISCU (show ISCU Antibodies) RNA levels were found in ~40% of tumors and this was significantly associated with HIF-1alpha (show HIF1A Antibodies) and CAIX (show CA9 Antibodies), but not MCT1 (show CMA1 Antibodies) or MCT4, over-expression.
High expression of MCT4 is associated with inflammation in arsenite-induced liver carcinogenesis.
The loss expression of Cav-1 on CAFs and the up-regulation of MCT4 may be the possible mechanisms of CAFs in tumorigenesis.
MCT1 (show CMA1 Antibodies) and MCT4 expression levels were associated with worse prognosis and shorter overall survival.
We demonstrated that the expression levels of glycolysis-related proteins glucose transporter 1 (show SLC2A1 Antibodies), hexokinase II, carbonic anhydrase IX (show CA9 Antibodies), and monocarbonylate transporter 4 differ between thyroid cancer subtypes and are correlated with poorer prognosis
Data suggest that inhibition of mnocarboxylate transporters MCT1 (show CMA1 Antibodies) and MCT4 may have clinical relevance in pancreatic ductal adenocarcinoma (PDAC).
MCT1 (show CMA1 Antibodies) inhibition impairs proliferation of glycolytic breast cancer cells co-expressing MCT1 (show CMA1 Antibodies) and MCT4 via disruption of pyruvate rather than lactate export.
MCT1 (show CMA1 Antibodies) expression was not clearly associated with overall or disease-free survival. MCT4 and CD147 expression correlate with worse prognosis across many cancer types. These results warrant further investigation of these associations
Prognostic significance of CD147 protein expression could not surpass that of MCT4, especially of SLC16A3 (show SLC16A3 Antibodies) DNA methylation (show HELLS Antibodies), corroborating the role of MCT4 as prognostic biomarker for ccRCC.
Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).
solute carrier family 16, member 4 (monocarboxylic acid transporter 5)
, solute carrier family 16, member 4
, monocarboxylate transporter 5
, monocarboxylate transporter 6
, solute carrier family 16 member 5
, MCT 4
, MCT 5
, monocarboxylate transporter 4
, solute carrier family 16 (monocarboxylic acid transporters), member 4